iShares NASDAQ Biotechnology Index (IBB) Stake Decreased by Eagle Global Advisors LLC

Eagle Global Advisors LLC lowered its position in iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 85.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 895 shares of the financial services provider’s stock after selling 5,315 shares during the period. Eagle Global Advisors LLC’s holdings in iShares NASDAQ Biotechnology Index were worth $262,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of IBB. Tarbox Group Inc. bought a new position in iShares NASDAQ Biotechnology Index during the first quarter worth approximately $104,000. Sei Investments Co. increased its position in shares of iShares NASDAQ Biotechnology Index by 297.0% in the first quarter. Sei Investments Co. now owns 401 shares of the financial services provider’s stock valued at $118,000 after buying an additional 300 shares during the last quarter. YorkBridge Wealth Partners LLC increased its position in shares of iShares NASDAQ Biotechnology Index by 174.8% in the first quarter. YorkBridge Wealth Partners LLC now owns 448 shares of the financial services provider’s stock valued at $134,000 after buying an additional 285 shares during the last quarter. FTB Advisors Inc. acquired a new position in shares of iShares NASDAQ Biotechnology Index during the first quarter valued at approximately $189,000. Finally, Foster & Motley Inc. acquired a new position in shares of iShares NASDAQ Biotechnology Index during the first quarter valued at approximately $205,000. 59.91% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

iShares NASDAQ Biotechnology Index (NASDAQ:IBB) traded down 0.79% during mid-day trading on Monday, hitting $288.22. The stock had a trading volume of 619,941 shares. iShares NASDAQ Biotechnology Index has a 52 week low of $240.30 and a 52 week high of $303.74. The company’s 50 day moving average price is $292.18 and its 200 day moving average price is $285.29.

COPYRIGHT VIOLATION WARNING: This piece of content was published by BBNS and is owned by of BBNS. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/eagle-global-advisors-llc-sells-5315-shares-of-ishares-nasdaq-biotechnology-index-ibb-updated/800201.html.

Several research analysts have commented on the company. Credit Suisse Group AG raised iShares NASDAQ Biotechnology Index from a “market weight” rating to an “overweight” rating in a research note on Tuesday, March 21st. They noted that the move was a valuation call. Vetr upgraded iShares NASDAQ Biotechnology Index from a “hold” rating to a “buy” rating and set a $303.00 price target on the stock in a report on Monday, May 8th.

About iShares NASDAQ Biotechnology Index

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Receive News & Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related companies with our FREE daily email newsletter.

 


Latest News

Zack Greinke Having Much Better Results This Season
Zack Greinke Having Much Better Results This Season
David Price and Red Sox to Meet Following Rehab Start
David Price and Red Sox to Meet Following Rehab Start
Lack of Offense Leading to Mediocrity for Boston Red Sox
Lack of Offense Leading to Mediocrity for Boston Red Sox
MLB and Facebook Announce Live Streaming for Games
MLB and Facebook Announce Live Streaming for Games
Can Anyway Stop the Houston Astros?
Can Anyway Stop the Houston Astros?
Kevin Pillar Turns from Defense to Offense
Kevin Pillar Turns from Defense to Offense


Leave a Reply

 
© 2006-2017 BBNS.